Nordson (NDSN) Q2 2026 Earnings Transcript

Nordson reported record quarterly sales of $741 million, up 8% year over year, with adjusted EPS of $2.86, up 18%, and free cash flow of $170 million. Management raised full-year guidance to $2.930 billion-$3.010 billion in sales and $11.30-$11.80 in adjusted EPS, citing 18% organic backlog growth and broad-based order momentum across all segments. The company also acquired CapstanAG for 9x adjusted EBITDA and continued capital returns with $46 million in dividends and $43 million in share repurchases.

Analysis

This print is less about an isolated beat and more about a reacceleration in the company’s operating cadence: broad-based order strength plus a backlog mix that is still mostly short-cycle means the next 1-2 quarters should remain relatively visible even if macro headlines stay noisy. The key second-order effect is that management is now converting growth into financial flexibility — sub-2x leverage, rising cash conversion, and active repurchases create a self-reinforcing setup where incremental operating upside can flow directly into EPS and buybacks rather than being absorbed by balance-sheet repair.

The market may underappreciate how diversified the demand base has become. If ATS is early-cycle while medical is merely normalizing and industrial is recovering, then this is not one end market’s beta trade; it is a portfolio mix shift that reduces the probability of a single-cycle air pocket. That matters because it lowers the chance that a slowdown in one vertical materially offsets the others, while margin resilience is being preserved through pricing, footprint changes, and SG&A leverage.

The main risk is that the current setup is more duration-sensitive than the headline guide suggests: if semiconductor or industrial capex pauses, the company’s high backlog confidence could fade quickly given the large share of orders that are still delivered within months. A second-order risk is that inflationary input pressure and customer-requested timing push margin expansion later than bulls expect, making the equity look expensive on near-term earnings multiple expansion even if the fundamental story stays intact. The most interesting contrarian angle is that the stock may already be discounting the good-news cadence, while the bigger upside is actually from capital allocation optionality over the next 2-4 quarters, not this quarter’s beat.

Key Decisions for Investors

• Long NDSN on a 3-6 month horizon via stock or call spreads; thesis is mid-single-digit organic growth plus buyback support. Risk/reward is attractive if the market is underpricing backlog conversion and EPS compounding, but trim if guide-to-consensus spreads start narrowing.
• Pair long NDSN / short an industrial cyclicals basket with more operating leverage to macro (e.g. XLI constituents with weaker recurring revenue) for a 1-2 quarter trade; NDSN’s shorter-cycle exposure and balance-sheet strength should outperform if growth stays uneven.
• Sell put spreads on NDSN into any post-earnings weakness over the next 2-4 weeks; downside is cushioned by cash flow and leverage, while upside remains tied to continued order momentum and capital returns.
• If semicap capex data rolls over, hedge NDSN with a tactical short in a semicap equipment proxy for 2-3 months; ATS is the cleanest near-term vulnerability because that is where the cycle sensitivity is highest.
• Do not chase a large breakout above recent highs without confirmation from next-quarter order trends; the better entry is a 5-8% pullback, where the free cash flow yield and buyback support should improve the risk/reward materially.